Kura's Komzifti sells $13.9m in quarter; FDA agrees darlifarnib trial design
The US oncology company posted third-quarter sales growth of 53% for its acute myeloid leukaemia drug and lined up a small salivary gland cancer study with regulators.
Kura Oncology booked $13.9 million in third-quarter 2026 sales of Komzifti (ziftomenib), its treatment for relapsed or refractory acute myeloid leukaemia (AML) with an NPM1 mutation. The company, which reported on 10 November, described the figure as a 53% increase. The information available does not say what period that growth is measured against, so the underlying trajectory cannot be fully assessed.
The company also pointed to its balance sheet. It ended the quarter with $492.1 million in cash and has signed a financing agreement with Oberland Capital worth up to $300 million, of which $55 million arrived at closing. The conditions and timing for drawing the remaining funds were not detailed.
In the pipeline, Kura said it has agreed with the US Food and Drug Administration (FDA) the design of a study meant to support registration of darlifarnib in salivary gland cancer driven by an HRAS mutation. The trial is planned as a single-arm study of about 40 patients, with a start expected in the first half of 2027. Endpoints were not included in the material available.
Why it matters
- Komzifti's $13.9m quarter gives an early read on uptake in a narrow, biomarker-defined AML setting, though the comparison base for the 53% growth is unstated.
- Cash of $492.1m plus access to up to $300m from Oberland (only $55m received so far) frames how much runway Kura has for commercial and clinical spending.
- A regulator-agreed, roughly 40-patient single-arm design points to a modest-sized development programme for darlifarnib, with the first patients not expected until 2027.
Company's press release (SEC filing): Kura Oncology, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
